A national evaluation analysis and expert interview study of real-world data sources for research and healthcare decision-making

Author:

Mikl Veronika1,Baltic Dejan1,Czypionka Thomas2,Degelsegger-Márquez Alexander3,Forgó Nikolaus4,Gouya-Lechner Ghazaleh1,Herzog Arnold5,Klimek Peter6,Lumenta David Benjamin7,Mraz Bernhard1,Ostermann Herwig3,Scharinger Robert8,Stamm Tanja1,Strassnig Michael9,Zeitlinger Markus1,Pleiner-Duxneuner Johannes1

Affiliation:

1. Gesellschaft für Pharmazeutische Medizin e.V. (GPMed)

2. Institut für Höhere Studien – Institute for Advanced Studies (IHS)

3. Gesundheit Österreich GmbH (GÖG)

4. University of Vienna

5. Austrian Medicines and Medical Devices Agency (AGES Medizinmarktaufsicht)

6. Supply Chain Intelligence Institute Austria (ASCII)

7. Medical University of Graz

8. Federal Ministry of Social Affairs, Health, Care and Consumer Protection

9. Wiener Wissenschafts-, Forschungs- und Technologiefonds (Vienna Science and Technology Fund)

Abstract

Abstract Real-world data (RWD) can provide intel (real-world evidence, RWE) for research and development, as well as policy and regulatory decision-making along the full spectrum of health care. Despite calls from global regulators for international collaborations to integrate RWE into regulatory decision-making and to bridge knowledge gaps, some challenges remain. In this work, we performed an evaluation of Austrian RWD sources using a multilateral query approach, crosschecked against previously published RWD criteria and conducted direct interviews with representative RWD source samples. This article provides an overview of 73 out of 104 RWD sources in a national legislative setting with favourable RWD incentives, which can be used to extrapolate to other EU data regions under the General Data Protection Regulation (GDPR) and upcoming legislation such as the European Health Data Space Act (EHDS). We were able to detect omnipresent challenges associated with data silos, variable standardisation efforts and governance issues. Our findings suggest a strong need for a national health data strategy and governance framework, which should inform researchers, as well as policy- and decision-makers to improve RWD-based research in the healthcare sector to ultimately support actual regulatory decision-making and provide strategic information for governmental health data policies.

Publisher

Research Square Platform LLC

Reference17 articles.

1. Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World;Burns L;Clin. Ther.,2022

2. Use of Real-World Evidence for International Regulatory Decision Making in Medical Devices;Valla V;Int. J. Digital Health.,2023

3. Trial designs using real-world data: The changing landscape of the regulatory approval process;Baumfeld AE;Pharmacoepidemiol Drug Saf.,2020

4. European Medicines Agency. High-quality data to empower data-driven medicines regulation in the European Union. News 10/10. URL: https://www.ema.europa.eu/en/news/high-quality-data-empower-data-driven-medicines-regulation-european-union (2022)

5. Opportunities and challenges in using real-world data for health care;Rudrapatna VA;J Clin Invest.,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3